Oliver Schlüter
Direttore Finanziario/CFO presso Novaliq GmbH
Profilo
Oliver Schlüter is currently the Chief Financial Officer & Managing Director at Novaliq GmbH since 2015.
Prior to this, he worked as a Finance Director at Apogenix AG.
He also worked as an Analyst at DZ Bank AG (Securities) in 2006.
Posizioni attive di Oliver Schlüter
| Società | Posizione | Inizio |
|---|---|---|
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Direttore Finanziario/CFO | 10/09/2015 |
Precedenti posizioni note di Oliver Schlüter
| Società | Posizione | Fine |
|---|---|---|
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Direttore Finanziario/CFO | 01/05/2010 |
| DZ Bank AG (Securities) | Analyst-Equity | 31/01/2006 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Apogenix AG
Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
| DZ Bank AG (Securities) | Finance |
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Health Technology |
- Borsa valori
- Insiders
- Oliver Schlüter
